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Patients who survive out-of-hospital ventricular tachy-
cardia or ventricular fibrillation are at risk of sudden
cardiac death and often return to hospital after initial
discharge. The frequency and duration of readmittance to
hospital are not well known. Thus, the purpose of this study
was to evaluate the impact of the implantable cardioverter
defibrillator on frequency and duration of hospitalizations.
Methods Between 1989 and 1993, 38 consecutive patients
who had drug-refractory ventricular tachyarrhythmias were
selected for the study. A total of 38 patients were implanted
with the implantable cardioverter-defibrillator in accord-
ance with the guidelines of the European Society of
Cardiology. This analysis includes 35 of the 38 patients
(92%). All hospitalizations which occurred one year before
and one year after were studied. Clinical information for all
patients was obtained by consulting medical records and by
interviewing personal general practitioners.
Results The annual number of hospitalizations before and
after implantation of the implantable cardioverter-
defibrillator was, respectively, 3-28 ± 2-38 hospitalizations/
patient/year and 0-88 ± 1-23 hospitalizations/patient/year
(/><005). Before implantation of the implantable
cardioverter-defibrillator, patients were hospitalized a mean
of 32-94 ±2418 days/patient/year and after, 9-31 ±32-14
days/patient/year (/><005). The number of hospitalizations
for cardiac reasons decreased by 90%. Before implantation,
the most frequent cause was ventricular tachyarrhythmia
(47 hospitalizations for ventricular tachycardia and eight
for ventricular fibrillation), while after implantation, it was
as a result of the shock from the implantable cardioverter-
defibrillator (11 hospitalizations). The number of hospital-
izations for non-cardiac reasons were similar in the two
time periods. Of the 35 patients, 26 (74%) had at least one
appropriate successful ventricular tachycardia interrupted
by the implantable cardioverter-defibrillator, while 17
patients (49%) had their ventricular fibrillation terminated.
There is a significant difference in the rate of hospitaliz-
ations to intensive care units (ICU) between the two
periods. Before implantation, 30% of hospital days were
spent in the ICU, with 3% after.
Conclusions This study documents that the implantable
cardioverter-defibrillator not only reduces the frequency
and duration of hospital stays, but reduces admissions to
the more expensive units in hospital. Taking into account
the reduction in hospitalizations, the payback period for the
implantation of an implantable cardioverter-defibrillator is
19 months.
(Eur Heart J 1996; 17: 1565-1571)
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Introduction
Out-of-hospital ventricular fibrillation or sustained
symptomatic ventricular tachycardia in patients with-
out an acute myocardial infarction is a life-threatening
event with a high risk of recurrence11~7]. They are also
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likely to have lengthy and expensive rehospitalizations
for repeated ventricular arrhythmias after initial dis-
charge. The frequency of and reasons for rehospitaliz-
ation after such events are still undetermined.
A widely accepted treatment for life-threatening
arrhythmias is the implantable cardioverter-
defibrillator18"121. By implanting an implantable
cardioverter-defibrillator in patients with cardiac ar-
rhythmias, the frequency and duration of hospitaliz-
ations may decrease. This decrease may translate into
cost savings for the health care provider.
The aim of this study was to evaluate the impact
of implantable cardioverter-defibrillator therapy on the
frequency and duration of hospitalizations. The study
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Table 1 Clinical characteristics
n
Male
Female
Age (years ± SD)
Symptoms of arrhythmia
Cardiac arrest
Syncope
Faintness-Dizziness
Palpitations
LV ejection fraction (% ± SD)
Cardiac diagnosis
Coronary disease
Idiopathic dilated cardiomyopathy
Arrhythmogenic right ventricular dysplasia
Other
35
34
1
54± 14
(range 16-72)
11
6
12
6
36± 13
(range 17-69)
26
4
3
2
LV = left ventricular.
consisted of tracking 38 consecutive patients 12 months
before and 12 months after implantation.
Methods
Study population
All hospital documents of 38 consecutive patients with
drug-refractory symptomatic ventricular tachyarrhyth-
mias or ventricular fibrillation who had an implantable
cardioverter-defibrillator implanted between 1989 and
1993 were retrospectively collected and studied. Two
patients were excluded because of incomplete clinical
information, a third patient was excluded because he
died of heart failure before the end of the study period.
The study's final analysis included data from 35
patients implanted with an implantable cardioverter-
defibrillator according to the guidelines of the European
Society of Cardiology*131, which require that only
patients with documented and reproducible ventricular
arrhythmias are implanted. There were 34 men and one
woman ranging in age from 16 to 72 years with a mean
of 54 ± 14 years. All patients gave their written informed
consent to the implantation. The presenting symptoms
of arrhythmia, left ventricular ejection fraction and the
cardiac diagnosis for each patient are summarised in
Table 1. At time of the implantation 14 patients were
on amiodarone treatment, five on sotalol, five on a class
I antiarrhythmic drug, two on a beta-adrenoreceptor
blocker and three on combined (class I + sotalol)
treatment.
After implantation, patient data were gathered
from regular evaluations in the pacemaker follow-up
centre at the University Hospital (Centre Hospitalier
Universitaire Vaudois) of Lausanne, Switzerland. Each
patient was examined every 3 months for automatic
tachycardia intervention, and results were reported and
documented by implantable cardioverter-defibrillator-
stored electrograms, if available.
Clinical information for all patients was continu-
ously collected and obtained by consulting medical/
hospital records and interviewing their personal general
practitioners. This information included all documents
concerning medical history, treatments and hospitaliz-
ations in the 12 months before and after implantable
cardioverter-defibrillator implantation. Therefore we
can provide data for the complete period of observation
(12 months before and 12 months after implantation)
for all patients. Special attention was given to the
number of hospitalizations, the primary reason for each
hospitalization, and the duration of hospital stay.
Patient hospitalizations before and after implan-
tation were then classified as either cardiac or non-
cardiac. Cardiac reasons included: (1) ventricular
fibrillation or ventricular tachycardia; (2) cardiac pro-
cedure or cardiovascular surgery; (3) suspicion of
inadequate functioning or shock from the implantable
cardioverter-defibrillator; (4) angina pectoris or acute
myocardial infarction; or (5) other. If a patient was
hospitalized for a cardiac procedure or cardiovascular
surgery, the reasons were further classified as: (a) percu-
taneous transluminal coronary angioplasty or coronary
artery bypass grafting; (b) electrophysiological study; (c)
prolonged monitoring of the implantable cardioverter-
defibrillator functions; or (d) other.
The study's primary focus was on the frequency
and duration of hospital stays before and after implan-
tation. Hospitalization during implantation is consid-
ered a secondary focus and will be documented in a
separate report.
The data are reported as mean values and stan-
dard deviation ( ± SD). The paired two-tailed Student's
t-test was used for statistical analysis. A P value of
<005 was considered statistically significant.
Results
Number of hospitalizations
The annual number of hospitalizations before implanta-
tion of the implantable cardioverter-defibrillators was
328 ±2-38 range (range 0-10) hospitalizations/patient/
year. After implantation, the number decreased to
0-88 ± 1 -23 (range 0-5) hospitalizations/patients/year
(/><005) (Table 2). In the year after implantation, the
percentage of patients not readmitted to the hospital
was significantly higher (48%) than in the year before
implantation (86%).
The majority of hospitalizations before and after
implantation were for cardiac reasons (Fig. 1), but the
primary cardiac reasons differed significantly in the two
periods studied (Fig. 2). Before implantation, there were
115 hospitalizations, with 108 (94%) for cardiac reasons.
The most frequent cause for hospitalization in this
case was ventricular arrhythmia, with 47 admissions
for ventricular tachycardia and eight for ventricular
fibrillation. In the time period after the first occurrence
of ventricular tachycardia or ventricular fibrillation
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Table 2 Main results
Before ICD
implantation
After ICD
implantation
Number of patients
Yearly number of hospitalizations
per patient
Yearly number of hospital days
per patient
Total hospital days
Number of hospital days for
cardiac reason
Number of hospitalizations for
arrhythmic events
Number of patients treated
with antiarrhythmic drugs
35
3-28 ±2-38*
Range (0-10)
32-94 ± 23-86*
Range (0-93)
1153
1085
55
(8 VF, 47 VT)
29
35
0-88 ± 1 23*
Range (0-5)
9-31 ±3214*
Range (0-188)
326
106
2
(atrial fibrillation)
16
*P<0-05
ICD = unplantable
fibrillation.
cardioverter-defibnllator; VT = ventricular tachycardia; VF = ventricular
120
100
80
60
40
(94^.
Figure 1 Number of hospitalizations in the two time
periods. Before ICD=hospitalizations in the year before
implantable cardioverter defibrillator implantation; after
ICD=hospitalizations in the year after implantable car-
dioverter defibrillator implantation; • = hospitalizations
for non-cardiac reasons; • = hospitalizations for cardiac
reasons.
and before implantation, the average number of
hospitalizations was 1-53 per patient (range 0-5).
After implantation, the number of hospitaliz-
ations dropped to 31, with 25 (81%) for cardiac reasons.
In this case, however, the frequent cause was hospital-
ization for observation after a shock delivered by the
implantable cardioverter-defibrillator (11 hospitaliz-
ations). Of the 35 patients, 26 (74%) had at least one
appropriate successful ventricular tachycardia inter-
rupted by the implantable cardioverter-defibrillator,
while 17 patients (49%) had their ventricular fibrillation
terminated, with some patients receiving up to 30
discharges.
Before and after implantation, another frequent
cause for patient hospitalization was cardiac procedure
or cardiovascular surgery. They caused 32 hospitaliz-
ations before implantation (28 for electrophysiological
study) and 10 after (six for prolonged monitoring of the
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Figure 2 Number of hospitalizations for cardiac reasons.
VT=ventricular tachycardia; VF=ventricular fibrillation;
AMI = acute myocardial infarction. ESI = Before (108
hospitalizations); • = After (25 hospitalizations).
functions of the implantable cardioverter-defibrillator;
two for pacemaker implantation; one for radiofrequency
ablation of the atrioventricular junction; and one for
surgery for an abdominal aortic aneurysm). Cardiac
revascularization procedures were all carried out before
implantation of the device (two percutaneous translumi-
nal coronary angioplasty and two coronary artery
bypass grafting)
The number of hospitalizations for non-cardiac
reasons were similar in the two time periods, with seven
hospitalizations before and six after implantation
(Fig. 1).
Duration of hospital stay
Before implantation of the implantable cardioverter-
defibrillator, patients were hospitalized a mean of
32-94 ±23-86 (range 0-93) days/patient/year and after
9-31 ± 3214 (range 0-188) days/patient/year.
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Figure 3 Days of hospitalization in the two time periods.
Before ICD=days of hospitalization in the year before
implantable cardioverter defibrillator implantation; after
ICD=days of hospitalization in the year after implant-
able cardioverter defibrillator implantation; • = d a y s
of hospitalization for non-cardiac reasons; D=days of
hospitalization for cardiac reasons.
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Figure 4 Days of hospitalization for cardiac reasons.
VT=ventricular tachycardia; VT=ventricular fibrillation;
AMI=acute myocardial infarction; E3 = Before (1085 hos-
pitalization days); • = After (106 hospitalization days).
The total number of hospital days for cardiac
reasons decreased by 90% after implantation. Ninety-
four percent of patients' time spent in hospital (1085
days) before implantation was due to a cardiac problem,
in contrast to 32% (106 days) in the year following (Figs
3 and 4). A major reason for hospitalization before
implantation of the device was for arrhythmic events
(581 days or 50% of the pre-implantable cardioverter-
defibrillator total hospital days) and 13 hospitalizations
were for antiarrhythmic drug testing (184 days or 16%
of the pre-implantable cardioverter-defibrillator total
hospital days). These included 16 cardiac arrests (all
occurred before implantation); 50% happened outside
the hospital and 50% during the hospital stay. Of the 35
patients analysed in our study, 25 (71 -4%) were cardio-
verted or defibrillated at least once during the year
before implantation (52 external shocks, range per
patient 1-5). After implantation, only one patient was
externally cardioverted for atrial fibrillation during hos-
pitalization and no additional drug testing was required.
After implantation, the major reason for hospi-
talization was related to the implantable cardioverter-
defibrillator (69 days), including prolonged monitoring
of the functions of the device or patients' low tolerance
to shocks. Each stay was brief (average 405 days, range
1-12), and generally patients were discharged after in-
terrogation of the implantable cardioverter-defibrillator.
There were no hospitalizations for inappropriate func-
tioning of the implantable cardioverter-defibrillator or
infection.
The total number of hospital days for non-
cardiac reasons is higher after implantation (220 days
after and 68 days before), but this is primarily due to
one patient who stayed in hospital for 165 days. The
patient suffered from a vascular complication of diabetes
mellitus requiring leg amputation and subsequent
physiotherapy.
Implantation of the implantable
cardioverter-defibrillator
The average length of hospitalization for implantable
cardioverter-defibrillator implantation was 17 days ±8 ,
with a minimum of 9 and a maximum of 43 days.
For the 29 patients who had at least one episode of
ventricular tachycardia or ventricular fibrillation, the
implantable cardioverter-defibrillator was implanted an
average of 116 days (range 16-304) after the first occur-
rence of ventricular tachyarrhythmias. The remaining
six patients in the study did not suffer from spontaneous
ventricular tachycardias during the year before im-
plantation. In these patients, however, it was poss-
ible, despite drug treatment, to induce rapid (>150)
ventricular tachycardia during an electrophysiological
study.
Cost analysis
Between the two periods, we observed a significant
difference in the number of ICU hospitalizations for the
36 patients in the study (including the man who died
from heart failure). Before implantation, 360 out of 1172
hospitalization days (30-7%) were spent in intensive care
unit. After implantation, ICU stays decreased to 3% or
11 days.
According to a cost-accounting analysis using
1991 cost estimates, one day spent in our centre's
intensive care unit costs an average of 2546 Swiss francs,
as compared to 954 Swiss francs in a general ward.
Because we noted a decrease of 9-69 days per patient
spent in ICU and 12-42 in general wards, we calculated
a cost reduction of 36 519 Swiss francs per patient. To
determine the cost effectiveness of the implantable
cardioverter-defibrillators, we considered the average
cost of the device and hospitalization during implanta-
tion (Table 3). Using a cost of 58 061 Swiss francs per
implantable cardioverter-defibrillator implantation, we
calculated that the payback period for an implantable
cardioverter-defibrillator investment is 19 months.
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Table 3 Cost analysis
Number of patients
Days spent in ICU per patient
Average cost for hospitalization in ICU
per patient ( = 2546 Friday)
Days spent in general ward per patient
Average cost for hospitalization in general
ward per patient (=954 Friday)
Cost for device per patient
Total cost per patient
Before
implantation
36
10
Fr. 25 460
22 56
Fr. 21 522
Fr. 46 982
After
implantation
36
0 31
Fr. 789
1014
Fr. 9674
Fr. 10 463
Implantation
of the ICD
36
111
Fr. 2826
15-97
Fr. 15 235
Fr.40 000
Fr. 58 061
ICD = implantable cardioverter-defibrillator.
Fr. = Swiss Francs.
Discussion
First used in 19801141, the automatic implantable defibril-
lator has been the subject of extensive studies, but most
used historical controls or non-randomized concurrent
patients to compare with the implantable cardioverter-
defibrillator-implanted patients'15"191. In spite of that,
the implantable cardioverter-defibrillator has become
the treatment of choice in patients resuscitated from
cardiac arrest'10-201. Using this device, there has been a
significant reduction in sudden cardiac death rates when
compared to historical controls'9'21"281.
In this study we compared the use of hospital
services in a 12 month period before and after implant-
able cardioverter-defibrillator implantation. As all ar-
rhythmias were refractory to drug treatment including
amiodarone, the defibrillator had to be considered as a
last treatment choice and therefore ethical considera-
tions prohibited randomization.
Reduction of hospitalizations after implantation
of this device is a topic which has been discussed by
many authors'81. However, in-depth cost-effectiveness
studies and quality-of-life assessments of implantable
cardioverter-defibrillator therapy have never been
performed before.
The present study reveals that the implantable
cardioverter-defibrillator reduces days of hospitalization
for cardiac reasons by 90%. Before implantation of the
implantable cardioverter-defibrillator, a major reason
for patient hospitalization was tachyarrhythmias. The
individuals had to endure long and costly stays in the
ICU and frequently required external shocks.
The effectiveness of the implantable cardioverter-
defibrillator in the treatment of ventricular tachy-
arrhythmias is demonstrated in our study because
hospitalization. decrease was primarily due to a reduc-
tion of tachyarrhythmia-related hospital admissions. To
further prove this point, study results show that of the
35 patients, 74% had at least one appropriate successful
ventricular tachycardia interrupted by the implantable
cardioverter-defibrillator and 49% had their ventricular
fibrillation terminated. The study shows a relatively high
rate of spontaneous ventricular arrhythmias after im-
plantation, but this may be explained by our restrictive
patient selection criteria detailed earlier in this report. In
particular, a significant difference in the rate of admis-
sions to intensive care unit was noted between the two
time periods. Therefore, this study also reveals that the
implantable cardioverter-defibrillator not only reduces
the number and days of hospitalizations, but reduces
admissions to the more expensive units in hospital.
Antiarrhythmic drug therapy vs implantable
cardio verter-defibrillator
It has been reported that implantable cardioverter-
defibrillator therapy as early intervention does not
necessitate excessive costs and may be as cost effective as
antiarrhythmic drug therapy'29"321. In the present study,
it is interesting to observe that, before implantation, 13
(11-3%) hospitalizations and 184 (159%) hospital days
were due to testing of antiarrhythmic drugs. After
implantation no further drug testing was performed.
Furthermore, before hospitalization for implantation
of the implantable cardioverter-defibrillator, 83% of
patients were treated with at least one antiarrhythmic
drug, but only 45% were discharged on antiarrhythmic
drugs after implantation (see Table 2).
Our study shows that the conventional therapeu-
tic strategy, which reserves the implantable cardioverter-
defibrillator for patients failing to respond to classical
antiarrhythmic treatment and to many diagnostic and
therapeutic procedures, significantly contributes to pro-
longed hospitalization stays which always translate into
high health care costs.
As a tertiary centre we have to deal mostly with
complex cases. Earlier referral might have given even
more favourable results.
Hospitalizations due to classic manifestations of
ischaemic heart disease (myocardial infarction or an-
gina) were also reduced. This reduction was probably
due to the benefit of myocardial revascularization in
some patients (two coronary artery bypass grafting and
two percutaneous transluminal coronary angioplasty)
before the implantable cardioverter-defibrillator was
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implanted. However, it is known that these procedures
do not reduce cardiac arrhythmias133'34'.
Another area which must be considered when
evaluating the cost-effectiveness of the implantable
cardioverter-defibrillator is the increase in patients'
productive hours. In general, patient acceptance of
the device is very high'35"371, with more than 50% of
the patients resuming work during the year after
implantation'37'381.
Because the study was designed with a follow-up
of 12 months after implantation, a valid survival analy-
sis was not the aim of this study. Nevertheless, the
overall survival rate at one year for our group is 97-2%,
which corresponds to current medical literature19'21"28'.
Conclusions
In 35 patients who received the implantable
cardioverter-defibrillator for drug-refractory ventricular
tachyarrhythmias, the number and duration of hospi-
talizations were significantly reduced.
By reducing hospitalization, the study also shows
that implantable cardioverter-defibrillator therapy can
be cost effective when compared to other medical inter-
ventions. The study suggests a payback period for the
implantable cardioverter-defibrillator of 1-5 years.
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